IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. - Wikidata - wikimedia - TriplyDB

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

http://www.wikidata.org/entity/Q44134557

about

Decision aids for people considering taking part in clinical trials Molecular cancer prevention: Current status and future directions Breast cancer chemoprevention: old and new approaches Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial.Breast Cancer Risk - Genes, Environment and Clinics.Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.Progression of Ductal Carcinoma in Situ from the Pathological Perspective.Chemoprevention of hormone receptor-negative breast cancer: new approaches needed Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention Statins and Breast Cancer: Future Directions in Chemoprevention.Targeted therapy for breast cancer prevention.Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.Nonhormonal management of hot flashes for women on risk reduction therapy.Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy).Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population.Network-pharmacology-based validation of TAMS/CXCL-1 as key mediator of XIAOPI formula preventing breast cancer development and metastasis.Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.Prevention of breast cancer in the context of a national breast screening programme

P2860

Q24187609-C6FB0AD7-A5E0-483A-BD77-87D76AB1F5D5 Q26797207-E4D33236-51E6-4016-B9AD-238EAA03A221 Q27693259-61098500-4742-4059-8DF7-764B7D377526 Q28080472-09C169D1-DDFA-47F8-95DC-19B77BB8DD4C Q33739214-3B4B7D2A-3621-4859-B04F-8806441EB0C6 Q33877375-0E2A4D6E-B937-4CD9-8528-94171DBBF133 Q34201805-4A499244-E130-4649-BD81-3922A1835E7B Q34577467-D54A1B17-45A6-4CB9-899A-536E60FBCF36 Q35879741-978ED692-7548-41FB-B719-AF2FBA643A1D Q35940085-6356B2FA-10B7-4A66-8945-B7A541C0441B Q36153371-FF719E66-FC9D-40FF-98FA-E093115C521C Q36947842-0E5D35CE-B3DF-4FED-8B8A-B246207D1372 Q37097084-5D08F701-9FD5-4479-A325-E24E2F929EB1 Q37119810-8F1EB9A3-2F1E-4223-83E9-3DE3A5FCBA3D Q37190825-24A1435B-0F45-4FF7-979C-363B3CF762D6 Q37577926-3D98407C-338D-4EAE-AD89-1251F70EF06A Q37579591-906820A7-F464-4EF5-B8B6-94BB5BCA54ED Q37955050-DA1E3FEC-325C-49D8-94DE-50D4A86E31F5 Q39201898-6E75CD3B-FE83-4AB7-9667-2EE711E2E470 Q39500972-DCB3483F-20B1-4CDA-A9F1-CBD360DC4916 Q44469560-6182FAB9-CEF6-4C2F-9DA9-1806929DB181 Q47098338-7FFA0D35-FBBE-406D-AC2D-C1944356691D Q47309977-EEBB446B-F1F5-4D13-ABDC-615DCD88A8AE Q57266562-F07A4111-DA9F-43C1-B9D4-694CA8A73299

P2860

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

http://www.wikidata.org/entity/Q44134557

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

IBIS II: a breast cancer preve ...... omatase inhibitor anastrozole.

@en

IBIS II: a breast cancer preve ...... omatase inhibitor anastrozole.

@nl

type

label

IBIS II: a breast cancer preve ...... omatase inhibitor anastrozole.

@en

IBIS II: a breast cancer preve ...... omatase inhibitor anastrozole.

@nl

prefLabel

IBIS II: a breast cancer preve ...... omatase inhibitor anastrozole.

@en

IBIS II: a breast cancer preve ...... omatase inhibitor anastrozole.

@nl

P1433

Q44134557-0734D177-639A-4133-A281-31D553B7F367

P1476

Q44134557-485E0506-5EAE-4E16-B8CE-528C9DD240F9

P2093

Q44134557-B0B48A57-ECE1-42EA-9201-212C23396CBC

P2860

Q44134557-03FC31B2-A719-4F8E-AD2E-0BEFB2AF0F10

Q44134557-06A47BED-9D6B-41C9-8E04-2875ECD1F3B6

Q44134557-0F9BCA26-85FB-4D91-9F57-E954C446EA46

Q44134557-162B5121-0EF1-4332-BE8A-3AC1C90E0EA3

Q44134557-1E19A5DB-CE98-4100-AA47-D11D09D4785E

Q44134557-1EEE5C1B-53B5-41B3-8DB4-4EE970997817

Q44134557-1F517477-196B-4A06-BACD-362C1E39ADDC

Q44134557-211EBB37-5045-4431-83D8-4EBF5EC2A47B

Q44134557-284F8E98-532B-4F05-89E4-2D3881FD712B

Q44134557-2A208411-3E47-4663-BFAB-FF7E85E08E26

P304

Q44134557-623489DC-8997-4048-B38E-469C877464A5

P31

Q44134557-3481C07D-12AF-4E00-AE4D-A7BF03DB9210

P356

Q44134557-59091B54-7C08-4ECD-B9F5-1090F9C4BB1B

P433

Q44134557-70FDA990-C746-44C2-8CCD-946B465B9CAC

P478

Q44134557-A4D62009-2586-4163-A6DA-D7A94E67A917

P577

Q44134557-798A8FE9-00CB-458E-8191-B1C8AADBF8E3

P698

Q44134557-E1615814-A01E-4453-BACD-5257C23F7003

P356

14737140.8.9.1377

P1433

Expert Review of Anticancer Therapy

P1476

IBIS II: a breast cancer preve ...... omatase inhibitor anastrozole.

@en

P2093

Jack Cuzick

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

The decrease in breast-cancer incidence in 2003 in the United States.

Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.

P304

1377-1385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.8.9.1377

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18759690

http://www.w3.org/2001/XMLSchema#string